WNK2 and melanoma: The clinical implementation of BRAF and MEK (mitogen-activated protein kinase kinase) inhibitor therapies has resulted in dramatic improvements in OS and progression-free survival (PFS) rates in patients with BRAF(+) advanced melanoma cases over the last few years [19,20,21,22].